Skip to content
Screener

UroGen Pharma URGN Q4 2025 Annual earnings

Reported March 2, 2026 · Before market open

Revenue$37.8MMiss by $2.1M
EPS-$0.54Miss by $0.02
Revenue estimate$39.9M
EPS estimate-$0.52

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$90.6M
EPS estimate$0.10

Financials

Q4 2025

Income statement

See full
Revenue$37.8M+54.0%
Net income-$26.4M+29.7%

Balance sheet

See full
Cash & equivalents$110.7M-35.6%
Total debt$131.4M+4.7%
Total equity-$105.5M-1,098%
Total assets$200.5M-29.8%

Cash flow

See full
Operating cash flow-$38.3M-181%
CapEx$17.0K-85.2%
Free cash flow-$38.3M-179%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.1B+144%
Enterprise value$1.12B+177%
P/S10×+5.0×

Profitability

See full
Net margin-139.8%-0.5pp
FCF margin-148.2%+91.0pp

Returns & leverage

See full
Current ratio4×-2.0×

Segments

By product

See full
Jelmyto$23.8M-3.0%

FAQ

When did UroGen Pharma report Q4 2025 earnings?
UroGen Pharma (URGN) reported Q4 2025 earnings on March 2, 2026 before market open.
What were UroGen Pharma's Q4 2025 revenue and EPS?
UroGen Pharma reported revenue of $37.8M and eps of $-0.54 for Q4 2025.
Did UroGen Pharma beat estimates in Q4 2025?
Revenue missed the consensus estimate of $39.9M by $2.1M. EPS missed the consensus estimate of $-0.52 by $0.02.
How did UroGen Pharma's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 54.0% from $24.6M a year earlier and eps grew 32.5% from $-0.80.
Where can I find UroGen Pharma's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-084282) and the 10-K periodic report (0001437749-26-006234) directly on SEC EDGAR. The filing index links above go to sec.gov.